Rezolute, Inc. (RZLT) - 10-Q Filing Summary
Business Context and Reporting Period
Company: Rezolute, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026 (Fiscal Q3 2026)
Business Overview: Rezolute is a late-stage rare disease company focused on developing therapies for hyperinsulinism (HI). Its primary asset is ersodetug, a potential universal treatment for HI. The company is currently enrolling in the Phase 3 upLIFT trial for tumor HI and is awaiting FDA feedback on the Phase 3 sunRIZE trial for congenital HI, which did not meet its primary or key secondary endpoints in December 2025.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Mar 31, 2026 | Nine Months Ended Mar 31, 2026 | Nine Months Ended Mar 31, 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(16,171) | $(57,095) | $(50,022) |
| Net Loss Per Share (Basic/Diluted) | $(0.16) | $(0.55) | $(0.72) |
| Operating Expenses | $17,366 | $61,404 | $54,044 |
| Research & Development (R&D) | $11,412 | $38,909 | $40,664 |
| General & Administrative (G&A) | $5,954 | $22,495 | $13,380 |
| Cash & Cash Equivalents (End of Period) | $11,236 | $11,236 (Mar 31, 2026) | |
| Marketable Debt Securities | $109,032 | ||
| Total Capital Resources | $120.2 million | ||
| Net Cash Used in Operating Activities (9mo) | $(51.5 million) | $(47.1 million) |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss for the nine months ended March 31, 2026, increased by $7.1 million compared to the prior year period, primarily driven by higher G&A expenses and share-based compensation.
- G&A Expense Surge: G&A expenses increased by $9.1 million (68%) year-over-year for the nine-month period. This was driven by a $4.4 million increase in compensation (including $3.3 million in share-based compensation) and $4.2 million in business development and market research costs.
- R&D Expense Decrease: R&D expenses decreased by $1.8 million (4%) year-over-year. This reduction was due to a $7.1 million decrease in ersodetug program costs (specifically manufacturing and process qualification), partially offset by increased clinical trial costs for the upLIFT study and severance expenses.
- Workforce Reduction: Following the sunRIZE trial results, the company reduced its workforce by 29 employees in December 2025, incurring $1.5 million in severance costs (recognized in Q2 FY2026).
- Liquidity Position: Cash and cash equivalents decreased from $94.1 million (June 30, 2025) to $11.2 million (March 31, 2026), while investments in marketable debt securities increased from $73.8 million to $109.0 million. Total capital resources remain at $120.2 million.
Guidance, Outlook, and Risks
- sunRIZE Trial (Congenital HI): The Phase 3 trial did not meet primary or key secondary endpoints. The FDA encouraged the company to submit comprehensive analysis datasets for independent evaluation. An update on the program is expected in the second half of calendar year 2026. The company believes the primary endpoint was confounded by behavioral factors and placebo effects.
- upLIFT Trial (Tumor HI): The company is enrolling in this Phase 3 registrational study. Enrollment and topline results are anticipated in the second half of 2026. The study design was modified to a single-arm, open-label trial following FDA agreement.
- Liquidity Outlook: Management believes current capital resources ($120.2 million) are sufficient to fund operations and clinical trials for at least 12 months from the filing date.
- Future Milestones: Significant contingent liabilities exist, including a $25.0 million regulatory milestone payment to XOMA upon approval of ersodetug and up to $25.0 million in clinical/regulatory milestones to ActiveSite. Additional sales-based milestones could total up to $202.5 million.
- Risks: Key risks include the potential rejection of sunRIZE datasets by the FDA, failure of the upLIFT trial to meet endpoints, and the need for additional financing to fund long-term operations and potential commercialization.
Investor Verification Checklist
- FDA Feedback on sunRIZE: Verify the timeline and outcome of the FDA's independent evaluation of the sunRIZE datasets, as this determines the path to potential marketing application or need for further studies.
- upLIFT Enrollment Status: Confirm the pace of patient enrollment in the upLIFT trial and any potential delays that could impact the H2 2026 topline data announcement.
- Cash Burn Rate: Monitor the monthly cash burn rate given the reduction in cash on hand to $11.2 million, despite the large investment portfolio, to assess the runway for the next 12 months.
- Share-Based Compensation: Review the impact of the $10.4 million in share-based compensation expense for the nine-month period on future dilution and cash flow.
- Legal Proceedings: Monitor for any filed litigation regarding the sunRIZE trial results, as several law firms have initiated investigations seeking stockholders to file suits.